Skip to main content
AGARWALEYE · Health Care · 2026-08-07

Dr. Agarwal's Health Care Ltd

MARKET: BULL TOPPING · 2026-08-07
₹546.3
+2.62% today
₹17,318 Cr · Mid cap
About this companyHealth Care· Hospitals & Diagnostic Centres
Expand ▾

Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.

Visit company website →
P/E (TTM)
115.1
Forward 57.9
Earnings Growth (YoY)
+20.8%
Revenue +22.6%
ROE
+8.3%
Profit margin +6.4%
vs 52W High
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 18
1w13w26w
Week 18 — proven structure, sweet spot
How long this stock has been basing. Longer bases can produce stronger breakouts — but don't anticipate, wait for the breakout.
vs 200 DMA
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.68x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
MA20 gently rising · +2.3% vs MA50 +3.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
Sector has 79 Stage 2 leaders. See Health Care Stage 2 →
Industry
Hospitals & Diagnostic Centres
↑ Building
Stage 2%
59.3%
20d Δ
+7.4pp
1M return
+1.2%
3M return
+9.0%
Industry Stage-2 % · last 20 days
Industry has 16 Stage 2 leaders. See Hospitals & Diagnostic Centres Stage 2 →
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2026-04-02 → 2026-08-07
S? 18w
2026-04-022026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 18w current
Total tracked: 18 weeks across 1 stage run.
1M
+12.5%
3M
+20.2%
6M
YTD
1Y
Scan Membership
Not in any current scan.
Recent Stage Timeline
2026-08-07S
Wk 18 · Vol x
2026-08-06S
Wk 18 · Vol x
2026-08-05S
Wk 17 · Vol x
2026-08-04S
Wk 17 · Vol x
2026-08-03S
Wk 17 · Vol x
2026-07-31S
Wk 17 · Vol x
2026-07-30S
Wk 17 · Vol x
2026-07-29S
Wk 16 · Vol x
2026-07-28S
Wk 16 · Vol x
2026-07-27S
Wk 16 · Vol x
2026-07-24S
Wk 16 · Vol x
2026-07-23S
Wk 16 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹476.9
200 DMA
52W High
52W Low
5D Low
₹483.3
Resistance levels (recent highs)
20d High
₹546.3
60d High
₹546.3
120d High
250d High
Next resistance
Above all

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.